Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00299182
Status:
COMPLETED
Last Update Posted:
2021-09-21
First Post:
2006-03-03
Brief Title:
Study of AMG 531 to Evaluate the Safety Efficacy in Patients With Non-Hodgkins Lymphoma
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Phase 12 Study of AMG 531 to Evaluate the Safety Efficacy and Pharmacokinetics in Patients With Aggressive Non-Hodgkins Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-CMTX
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to find the highest safe dose of AMG 531 that can be given to treat thrombocytopenia low platelet counts in patients who have received chemotherapy Researchers will also look at the safety and effectiveness of AMG 531
Primary Objectives
1 To determine the clinical safety and tolerability of AMG 531 administered following chemotherapy R-HyperCVAD alternating with R-Ara-CMTX in patients with non-Hodgkins lymphoma
2 To determine an optimal biologic dose OBD of AMG 531 in patients receiving R-HyperCVAD and R-Ara-CMTX
3 To evaluate the effects of AMG 531 on the degree and duration of thrombocytopenia and platelet recovery following chemotherapychemo
Secondary Objectives
1 To evaluate limited pharmacokinetics of AMG 531 administered by SC route with chemotherapy
Primary Objectives
1 To determine the clinical safety and tolerability of AMG 531 administered following chemotherapy R-HyperCVAD alternating with R-Ara-CMTX in patients with non-Hodgkins lymphoma
2 To determine an optimal biologic dose OBD of AMG 531 in patients receiving R-HyperCVAD and R-Ara-CMTX
3 To evaluate the effects of AMG 531 on the degree and duration of thrombocytopenia and platelet recovery following chemotherapychemo
Secondary Objectives
1 To evaluate limited pharmacokinetics of AMG 531 administered by SC route with chemotherapy
Detailed Description:
Platelets are cells that help make the blood clot A decrease in platelets can cause bleeding which may prevent or delay a patient from receiving chemotherapy R-HyperCVAD rituximab cyclophosphamide vincristine doxorubicin and dexamethasone and R-Ara-CMTX rituximab cytarabine and methotrexate are two chemotherapy regimens that are known to increase the risk of lower platelet counts Researchers want to find out if AMG 531 can lower the risk and severity of this side effect AMG 531 is a protein that stimulates platelet production
Before you can start treatment on this study you will have what are called screening tests These tests will help the doctor decide if you are eligible to take part in the study You will have a complete medical history and physical exam including measurement of vital signs temperature pulse breathing rate and blood pressure You will have blood collected about 3 teaspoons for routine tests Radiologic tests such as CT or MRI scans will be done as needed Women who are able to have children must have a negative blood pregnancy test
You will also have about 1 teaspoon of blood drawn to see if the you have antibodies to the study drug
If you are found to be eligible to take part in this study you will be randomly assigned as in the toss of a coin to one of four treatment groups These 4 groups will also be split into 2 separate subgroups Arm A and Arm B Participants in Arm A will either receive AMG 531 or placebo on Day -5 5 days before chemotherapy starts and Day 5 5 days after chemotherapy starts A placebo is a substance that looks like the study drug but which has no active ingredients Every 2 out of 3 participants in Arm A will receive AMG 531 One out of every 3 participants in Arm A will receive placebo
Participants in Arm B will receive either AMG 531 or placebo on Day 5 and 7 Every 2 out of 3 participants in Arm B will receive AMG 531 One out of every 3 participants in Arm B will receive placebo The dose of AMG 531 that participants in both Arms A and B receive will depend on when they enroll on the study There are 3 different dose levels of AMG 531 being studied Each new group of participants will receive a higher dose than the previous group
All participants will receive treatment with R-HyperCVAD and R-Ara-CMTX chemotherapy by vein in alternating cycles In Cycle 1 all participants will receive R-HyperCVAD by itself Each cycle is 3 weeks long
Three 3 weeks later in Cycle 2 all participants will receive either AMG 531 or placebo following R-Ara-CMTX The AMG 531placebo will be given as an injection under the skin on Days -5 and 5 Arm A or on Days 5 and 7 Arm B After 2 cycles of treatment based on response of the disease and tolerance to the treatment all participants may be able to receive up to 4 more cycles of chemotherapy followed by AMG 531 For Cycles 3-6 you will follow the same schedule of therapy as in the first 2 cycles The dose of AMG 531 may be increased at one time point during the study based on the response of the platelet counts
Blood about 1 teaspoon will be collected for the evaluation of anti-AMG 531 antibody status at the end of Cycles 2 and 4 You will be taken off the study if your disease gets worse or intolerable side effects occur The number of blood tests drawn will depend on your clinical condition These samples about 1 teaspoon each will be taken at least 2 times a week and as often as once a day during anticipated periods of low blood cell counts
At the end of the study you will have an interim medical history and physical exam including measurement of vital signs You will have blood about 1 teaspoon drawn for routine end-of-study analysis Blood about 1 teaspoon will also be collected for the evaluation of anti-AMG 531 antibody status
This is an investigational study R-HyperCVAD and R-Ara-CMTX are commercially available chemotherapy drugs AMG 531 is not FDA approved or commercially available At this time AMG 531 is being used in this study for research purposes only About 36 evaluable patients maximum of 50 patients will take part in this study All will be enrolled at University of Texas UT M D Anderson
Before you can start treatment on this study you will have what are called screening tests These tests will help the doctor decide if you are eligible to take part in the study You will have a complete medical history and physical exam including measurement of vital signs temperature pulse breathing rate and blood pressure You will have blood collected about 3 teaspoons for routine tests Radiologic tests such as CT or MRI scans will be done as needed Women who are able to have children must have a negative blood pregnancy test
You will also have about 1 teaspoon of blood drawn to see if the you have antibodies to the study drug
If you are found to be eligible to take part in this study you will be randomly assigned as in the toss of a coin to one of four treatment groups These 4 groups will also be split into 2 separate subgroups Arm A and Arm B Participants in Arm A will either receive AMG 531 or placebo on Day -5 5 days before chemotherapy starts and Day 5 5 days after chemotherapy starts A placebo is a substance that looks like the study drug but which has no active ingredients Every 2 out of 3 participants in Arm A will receive AMG 531 One out of every 3 participants in Arm A will receive placebo
Participants in Arm B will receive either AMG 531 or placebo on Day 5 and 7 Every 2 out of 3 participants in Arm B will receive AMG 531 One out of every 3 participants in Arm B will receive placebo The dose of AMG 531 that participants in both Arms A and B receive will depend on when they enroll on the study There are 3 different dose levels of AMG 531 being studied Each new group of participants will receive a higher dose than the previous group
All participants will receive treatment with R-HyperCVAD and R-Ara-CMTX chemotherapy by vein in alternating cycles In Cycle 1 all participants will receive R-HyperCVAD by itself Each cycle is 3 weeks long
Three 3 weeks later in Cycle 2 all participants will receive either AMG 531 or placebo following R-Ara-CMTX The AMG 531placebo will be given as an injection under the skin on Days -5 and 5 Arm A or on Days 5 and 7 Arm B After 2 cycles of treatment based on response of the disease and tolerance to the treatment all participants may be able to receive up to 4 more cycles of chemotherapy followed by AMG 531 For Cycles 3-6 you will follow the same schedule of therapy as in the first 2 cycles The dose of AMG 531 may be increased at one time point during the study based on the response of the platelet counts
Blood about 1 teaspoon will be collected for the evaluation of anti-AMG 531 antibody status at the end of Cycles 2 and 4 You will be taken off the study if your disease gets worse or intolerable side effects occur The number of blood tests drawn will depend on your clinical condition These samples about 1 teaspoon each will be taken at least 2 times a week and as often as once a day during anticipated periods of low blood cell counts
At the end of the study you will have an interim medical history and physical exam including measurement of vital signs You will have blood about 1 teaspoon drawn for routine end-of-study analysis Blood about 1 teaspoon will also be collected for the evaluation of anti-AMG 531 antibody status
This is an investigational study R-HyperCVAD and R-Ara-CMTX are commercially available chemotherapy drugs AMG 531 is not FDA approved or commercially available At this time AMG 531 is being used in this study for research purposes only About 36 evaluable patients maximum of 50 patients will take part in this study All will be enrolled at University of Texas UT M D Anderson
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None